AstraZeneca Korea to launch fulvestrant, new treatment option for advanced breast cancer

Published: 2008-11-03 06:45:00

Updated: 2008-11-03 06:45:00

AstraZeneca Korea has announced that it will launch fulvestrant (Faslodex 250mg), a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It received approval from the nation’s food and drug authoriti...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK